A recent study found the number of health insurers offering broad provider networks on the Obamacare exchange was higher than in all but 10 other states and suggests that so long as Hoosiers keep singing “Don’t Fence Me In,” they could keep paying more for health insurance.
Calibrium LLC and MB2 LLC, both based in Carmel, have agreed to be sold for undisclosed amounts. They were developing diabetes drugs discovered by the research team of Richard DiMarchi, a chemistry professor at Indiana University.
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
Although the $10 million Pike Township YMCA has no timetable for completion, officials have pledged to offer extensive services to veterans in conjunction with the Richard L. Roudebush VA Medical Center.
Eli Lilly and Co. didn’t win approval for a new drug last week. But its latest study of an existing diabetes drug could create a blockbuster in its own right—adding as much as $1 billion a year to the coffers of the Indianapolis-based drugmaker.
Profits at most county-owned hospitals have grown by 100 percent to 400 percent over the past four years via partnerships with nursing homes that have brought in hundreds of millions of dollars in extra federal money.
The IU Board of Trustees gave unanimous approval to the 45,000-square-foot addition to the school at IUPUI. It is expected to open in 2020.
Dr. Bill Tierney, who has led the Regenstrief medical informatics research operation for five years, will become chair of the department of population health at the Dell Medical School at the University of Texas at Austin.
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
Concerns about serious side effects, including fainting, complicate discussions about whether to cover Sprout Pharmaceuticals' Addyi.
The Food and Drug Administration on Tuesday approved the first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to replicate the blockbuster success of impotence drugs for men.
Biotech drugmaker Amgen will pay $71 million to settle an investigation into illegal marketing of its drugs Aranesp and Enbrel, ending an investigation by 48 states and Washington, D.C.
According to an internal memo, employees at Indiana University Health “lack confidence in senior leadership” and don’t think they are consistently provided adequate resources to serve patients. IU Health leaders have vowed to fix that.
Catheter Research Inc.—which makes single-use medical devices, such as catheters—plans a $4.8 million expansion that will relocate its headquarters to larger space on the northwest side.
Hoosier entrepreneurs in health care and life sciences attracted more than $31 million from investors during the first half of the year. But too few Indiana companies have developed their technology enough to attract venture capitalists or tap stock markets.
The new head of research at the Indiana University School of Medicine thinks the institution is missing out on the more than $6 billion spent each year in the United States on clinical trials.
Some patients who had their personal information compromised by a data breach at an Indiana medical software company are having trouble signing up for two years of free credit monitoring and identity protection.
Strand Diagnostics lost a key court battle on July 30 when a federal judge in Indianapolis granted summary judgment in favor of the Medicare program, which has refused to reimburse Strand for its test since 2012.
The federal government says it wants Lance Armstrong's medical records from his 1996 cancer treatments because they could prove just how far he was willing to go to conceal performance-enhancing drug use from the public and his sponsors.
A jury found Lilly isn't liable for withdrawal symptoms experienced by a woman who quit the antidepressant Cymbalta. The verdict may give the drugmaker leverage in fending off more than 5,000 other lawsuits over the drug.
